Neutralization of Enoxaparine-lnduced Bleeding by Protamine Sulfate

Summary

It has been suggested that protamine sulfate is a poor antidote for the bleeding side-effeets of low molecular weight heparins (LMWHs) in vivo, since protamine sulfate does not completely neutralize the anti-factor Xa activity of LMWHs in vitro or ex vivo. Therefore, we performed experiments to compare directly the abilities of protamine sulfate to neutralize the anticoagulant activities of the LMWH, enoxaparine, and unfractionated heparin ex vivo, with its ability to neutralize the bleeding side-effeets of both compounds in vivo. Bleeding was measured as the amount of blood lost from 5 cuts made in rabbits ears before and after treatment with enoxaparine or unfractionated heparin ± protamine sulfate. Plasma anti-factor Xa and anti-thrombin activities ex vivo, were measured chromogenically. Doses of 400 and 1,500 anti-factor Xa U/kg of heparin and enoxaparine, respectively, were required to enhance blood loss to the same extent. Protamine sulfate completely neutralized blood loss induced by both compounds, but did not neutralize the anti-factor Xa nor antithrombin activities ex vivo. We conclude that protamine sulfate is an effective antidote for the bleeding side-effeets of enoxaparine and unfractionated heparin, despite its inability to completely neutralize their anticoagulant activities.

• References

• 1 Jaques LB, Kavanagh LW. Protamine neutralization factors for heparin. Can J Pharm Sci 1977; 12: 44-47
• 2 Umlas J, Taff RH, Gauvin G, Swierk P. Anticoagulant monitoring and neutralization during open heart surgery – a rapid method for measuring heparin and calculating safe reduced protamine doses. Ancsth Analg 1983; 62: 1095-1099
• 3 Dutton DA, Hothersall AP, McLaren AD, Taylor KM, Turner MA. Protamine titration after cardiopulmonary bypass. Anaesthesia 1983; 38: 264-268
• 4 Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A, Pascariello JC, Weill D, Butel J. Prevention of postoperative venous thrombosis: A randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemostas 1988; 60: 407-410
• 5 Janvier G, Winnock S, Dugrais G, Vallet A, Dardel E, Scrise JM, Calen S, Vergnes C, Toulemonde F. Treatment of deep vein thrombosis with a very low molecular weight heparin fragment (CY222). Haemostasis 1987; 7: 49-58
• 6 Koller M, Schoch U, Buchmann P, Largiader F, von Felten A, Frick PG. Low molecular weight heparin (KAB1 2165) as thromboprophylaxis in elective visceral surgery. Thromb Haemostas 1986; 56: 243-246
• 7 Turpie A GG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull R, Gent M. A randomized controlled trial of a low molecular-weight heparin (Enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929
• 8 Thomas DP, Barrowcliffe TW, Curtis AD. Low molecular weight heparin: A better drug. Haemostasis 1986; 16: 87-92
• 9 Barrowcliffe TW, Johnson EA, Eggleton CA, Kemball-Cook G, Thomas DP. Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haematol 1979; 41: 573-583
• 10 Racanelli A, Fareed J, Walenga JM, Coyne E. Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments. Sem Thromb Hemostas 1985; 11: 176-189
• 11 Lindblad B, Borgstrom A, Wakefield TW, Whitehouse WM, Stanley JC. Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors. Thromb Res 1987; 48: 31-40
• 12 Gram J, Mercker S, Bruhn HD. Does protamine chloride neutralize low molecular weight sufficiently. Thromb Res 1988; 52: 353-359
• 13 Buchanan MR, Ofosu FA, Fernandez F, Van Ryn J. Lack of relationship between enhanced bleeding induced by heparin and other sulfated polysaccharides and enhanced catalysis of thrombin inhibition. Sem Thromb Hemostas 1986; 12: 324-327
• 14 Van Ryn-McKennaJ, Ofosu FA, Hirsh J, Buchanan MR. Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation. Br J Haematol 1989; 71: 265-269
• 15 Fernandez F, N-guyen P, Van Ryn F, Ofosu DA, Hirsh J, Buchanan MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986; 43: 491-495
• 16 Doutrepuich C, Bonini F, Toulemonde F, Bertrand H, Bayrou B, Quilichini R. In vivo neutralization of low-molecular weight heparin fraction CY216 by protamine. Sem Thromb Hemostas 1985; 11: 318-322
• 17 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
• 18 Ofosu FA, Modi GJ, Smith LM, Cerskus AL, Hirsh J, Blajchman MA. Heparin sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 1984; 64: 742-747
• 19 Rosner BA. Fundamentals of Biostatistics. P. W. S. Publishers; Boston, MA: 1982: 439
• 20 Harenberg J, Gnasso A, de Vries JX, Zimmermann R, Augustin J. Inhibition of low molecular weight heparin by protamine chloride in vivo. Thromb Res 1985; 38: 11-20
• 21 Diness V, Ostergaard PB. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats. Thromb Haemostas 1986; 56: 318-322